Eloi Espin
Overview
Explore the profile of Eloi Espin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
332
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guardiola J, Garcia-Iglesias P, Rodriguez-Moranta F, Brullet E, Salo J, Alba E, et al.
Gastroenterol Hepatol
. 2013 Jun;
36(8):534-45.
PMID: 23790810
No abstract available.
2.
Giralt J, Tabernero J, Navalpotro B, Capdevila J, Espin E, Casado E, et al.
Radiother Oncol
. 2008 Sep;
89(3):263-9.
PMID: 18768230
Purpose: The aim this study was to determine the pathologic complete response (pCR) rate defined as tumor regression grade 1 (TRG1) and toxicity profile of the combination of high-dose pre-operative...
3.
Giralt J, Navalpotro B, Hermosilla E, de Torres I, Espin E, Reyes V, et al.
Oncology
. 2007 Aug;
71(5-6):312-9.
PMID: 17687192
Purpose: To analyze the prognostic value of cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in patients with locally advanced rectal cancer treated with preoperative radiotherapy. Methods: Eighty-one patients with...
4.
Alazzouzi H, Suriano G, Guerra A, Plaja A, Espin E, Armengol M, et al.
J Med Genet
. 2006 Jul;
44(1):75-80.
PMID: 16825434
Background: Mdm2 is a natural inhibitor of p53 function and its overexpression impairs p53 transcriptional activity. T-->G single-nucleotide polymorphism at position 309 (SNP309) of mdm2 induces overexpression of mdm2, but...
5.
Alazzouzi H, Davalos V, Kokko A, Domingo E, Woerner S, Wilson A, et al.
Cancer Res
. 2005 Nov;
65(22):10170-3.
PMID: 16288001
The receptor tyrosine kinase EPHB2 has recently been shown to be a direct transcriptional target of TCF/beta-catenin. Premalignant lesions of the colon express high levels of EPHB2 but the expression...
6.
Giralt J, Heras M, Cerezo L, Eraso A, Hermosilla E, Velez D, et al.
Radiother Oncol
. 2005 Apr;
74(2):101-8.
PMID: 15816107
Background And Purpose: Expression of epidermal growth factor receptor (EGFR) is observed in 50-70% of colorectal carcinoma and is associated with poor prognosis. The aim of this study was to...
7.
Domingo E, Niessen R, Oliveira C, Alhopuro P, Moutinho C, Espin E, et al.
Oncogene
. 2005 Mar;
24(24):3995-8.
PMID: 15782118
Recently, it was shown that the oncogenic activation of BRAF, a member of the RAS/RAF family of kinases, by the V600E mutation is characteristic for sporadic colon tumors with microsatellite...
8.
Azem J, Lopez-Cano M, Ponseti J, Espin E, Sanchez J, Armengol M
Int J Colorectal Dis
. 2005 Jan;
20(6):549-50.
PMID: 15650827
No abstract available.
9.
Alazzouzi H, Domingo E, Gonzalez S, Blanco I, Armengol M, Espin E, et al.
Hum Mol Genet
. 2004 Nov;
14(2):235-9.
PMID: 15563510
Microsatellite instability (MSI) characterizes tumors arising in patients with hereditary non-polyposis colorectal cancer (HNPCC) syndrome. HNPCC is a hereditary autosomal dominant disease caused by germline mutations in genes from the...
10.
Domingo E, Espin E, Armengol M, Oliveira C, Pinto M, Duval A, et al.
Genes Chromosomes Cancer
. 2003 Dec;
39(2):138-42.
PMID: 14695993
BRAF, a serine/threonine kinase of the RAF family, is a downstream transducer of the RAS-regulated MAPK pathway and signals upstream of MEK1/2 kinases. Recently, activating mutations within BRAF have been...